InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
OtherDisclosed buys
5
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the complete record of transactions filed by Leavitt Chase C.. Director active across 1 company, notably Oncternal Therapeutics, Inc.. Cumulatively, 11 reports have been logged. Breakdown: 5 buys · 0 sell. Total volume traded: €44k. Activity tracked since 11 June 2021. The latest transaction was filed on 3 January 2024 (Retenue fiscale). Regulator: SEC (Form 4). The full history is free.
Declarations11 total
11,838 shares@ US$0.49619.1% of flowCommon StockSEC:0001209191-24-000971:0
10,305 shares@ US$0.365.8% of flowCommon StockSEC:0001209191-23-041318:0
15,000 shares@ US$0.296.7% of flowCommon StockSEC:0001209191-23-024264:0
Ideal exit: 7 Jan 2024 (T+270)
6,091 shares@ US$1.029.9% of flowCommon StockSEC:0001209191-23-002031:0
43,125 shares0Common StockSEC:0001209191-22-043739:0
8,500 shares@ US$1.7833.4% of flowCommon StockSEC:0001209191-22-005558:0
Ideal exit: 24 Oct 2022 (T+270)
8,500 shares@ US$1.7822.9% of flowCommon StockSEC:0001209191-22-005558
Ideal exit: 24 Oct 2022 (T+270)
29,867 shares0Common StockSEC:0001209191-22-001973
29,867 shares0Common StockSEC:0001209191-22-001973:0
1,500 shares@ US$5.4511.4% of flowCommon StockSEC:0001209191-21-040701
Ideal exit: 8 Mar 2022 (T+270)
1,500 shares@ US$5.4516.6% of flowCommon StockSEC:0001209191-21-040701:0
Ideal exit: 8 Mar 2022 (T+270)
11 of 11 declarations
About Leavitt Chase C.
Chase C. Leavitt is a director at Oncternal Therapeutics, Inc.
